Primary Aldosteronism with Parathyroid Hormone Elevation: A Single-center Retrospective Study

Area of Science:

• Endocrinology
• Hypertension Research

Background:

• Primary aldosteronism (PA) is a significant cause of secondary hypertension.
• The relationship between PA and other endocrine disorders, specifically parathyroid hormone (PTH) levels, remains poorly understood.

Purpose of the Study:

• To investigate the association between parathyroid hormone (PTH) levels and primary aldosteronism (PA) subtypes.
• To determine if PTH levels correlate with specific PA treatments and outcomes.

Main Methods:

• A retrospective analysis of 135 PA patients with pre-treatment PTH measurements.
• Evaluation of PTH levels in relation to PA subtypes (unilateral vs. bilateral) and treatment modalities.
• Correlation analysis between PTH values, basal plasma aldosterone concentration (PAC), and PAC post-captopril challenge.

Main Results:

• Over 30% of PA patients exhibited elevated PTH levels.
• PTH values showed a significant correlation with both basal PAC and PAC after captopril challenge.
• No significant difference in PTH levels was observed between unilateral and bilateral PA subtypes.
• Serum PTH levels decreased following treatment with unilateral adrenalectomy or mineralocorticoid receptor antagonists.

Conclusions:

• PTH levels in PA patients may reflect autonomous aldosterone production.
• No correlation was found between PTH levels and PA subtypes in this study.
• Targeted PA treatments can lead to a reduction in serum PTH levels.
• PTH may serve as a potential biomarker for assessing PA treatment suitability.